DOCSLIB.ORG

Constipation and Laxative Use in the Community

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Constipation and Laxative Use in the Community Constipation and Laxative Use in the Community Barry L. Werth Bachelor of Pharmacy (Honours) (University of Queensland) Master of Business Administration (Deakin University) A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Susan Wakil School of Nursing and Midwifery Faculty of Medicine and Health The University of Sydney 2019 Dedication To the memory of Helen “Trean” Werth RN (1954 - 2013) who would have preferred the thesis title: “Constipation and Aperient Use in the Community” ii Table of Contents Statement of originality viii Publications and conference presentations arising from this research ix Authorship attribution statement x Acknowledgements xii Abstract xiv List of abbreviations xvii List of tables xviii List of figures xx List of appendices xxi Glossary of terms xxii Chapter 1: Introduction 1 1.1 Background 2 1.1.1 Constipation: Definition and classification 4 1.1.2 Prevalence of constipation in the community 6 1.1.3 Factors associated with constipation in population-based studies 6 1.1.4 Laxative use: Definition and classification 8 1.1.5 Prevalence of laxative use in the community 10 1.1.6 Characterisation of laxative use 10 1.2 Research aims and objectives 12 1.3 Thesis outline 12 1.4 Significance of this research 16 1.5 References 17 Chapter 2: Epidemiology of constipation in adults: why estimates of prevalence differ 25 2.1 Abstract 26 2.2 Introduction 27 2.3 Methods 29 2.4 Search results 30 2.5 Prevalence of constipation 31 iii 2.5.1 Prevalence estimates in general adult populations 31 2.5.2 Prevalence estimates in older adult populations 40 2.6 Why prevalence estimates differ 43 2.6.1 Country/region 43 2.6.2 Definition of constipation 43 2.6.3 Data collection method 45 2.6.4 Sample characteristics 46 2.7 Conclusion 47 2.8 References 49 Chapter 3: Defining constipation to estimate its prevalence in the community: results from a national survey 57 3.1 Abstract 58 3.2 Introduction 59 3.3 Methods 60 3.3.1 Study population 60 3.3.2 Constipation definitions 61 3.3.3 Sample size 63 3.3.4 Analysis 63 3.3.5 Ethics approval 64 3.4 Results 65 3.4.1 Study population 65 3.4.2 Prevalence 67 3.4.3 Performance of simple definitions 69 3.5 Discussion 71 3.6 Conclusion 74 3.7 References 75 Chapter 4: Chronic constipation in the community: a national survey of Australian adults 78 4.1 Abstract 79 4.2 Introduction 80 iv 4.3 Methods 81 4.3.1 Study design and population 81 4.3.2 Questionnaire design 81 4.3.3 Sample size 82 4.3.4 Analysis 82 4.3.5 Ethics approval 83 4.4 Results 83 4.4.1 Study population and prevalence of chronic constipation 83 4.4.2 Factors associated with chronic constipation 85 4.5 Discussion 89 4.5.1 Prevalence of chronic constipation 89 4.5.2 Factors associated with chronic constipation 89 4.5.3 Strengths and limitations 91 4.6 Conclusion 92 4.7 References 93 Chapter 5: Use of over-the-counter laxatives by community-dwelling adults to treat and prevent constipation: a national cross-sectional study 97 5.1 Abstract 98 5.2 Introduction 99 5.3 Methods 100 5.3.1 Study population and recruitment 100 5.3.2 Survey questionnaire 101 5.3.3 Sample size 102 5.3.4 Analysis 102 5.3.5 Ethics approval 102 5.4 Results 103 5.5 Discussion 110 5.5.1 Utilisation of laxatives 110 5.5.2 Healthcare professional recommendation of laxatives 112 5.5.3 Effectiveness of laxatives 113 v 5.5.4 Strengths and limitations 114 5.6 Conclusion 114 5.7 References 115 Chapter 6: Laxative use and self-reported constipation in a community-dwelling elderly population 119 6.1 Abstract 120 6.2 Introduction 121 6.3 Methods 122 6.3.1 Data source 122 6.3.2 Study population and inclusion criteria 122 6.3.3 Constipation 123 6.3.4 Medications and laxative use 123 6.3.5 Potential risk factors for constipation 123 6.3.6 Statistical analyses 124 6.3.7 Ethics approval 124 6.4 Results 124 6.4.1 Study population characteristics 124 6.4.2 Laxative use 126 6.4.3 Constipation prevalence and risk factors 128 6.5 Discussion 132 6.6 Conclusion 135 6.7 References 136 Chapter 7: A longitudinal study of constipation and laxative use in a community-dwelling elderly population 139 7.1 Abstract 140 7.2 Introduction 141 7.3 Methods 143 7.3.1 Data source 143 7.3.2 Study population 143 7.3.3 Self-reported constipation 144 vi 7.3.4 Medication use 144 7.3.5 Potential risk factors for constipation 144 7.3.6 Analysis 145 7.4 Results 145 7.4.1 Study population 145 7.4.2 Constipation 147 7.4.3 Laxative use 150 7.4.4 Constipation and laxative use 151 7.5 Discussion 151 7.5.1 Constipation 151 7.5.2 Laxative use 153 7.5.3 Limitations 154 7.6 Conclusion 156 7.7 References 157 Chapter 8: Discussion, conclusion & future research directions 161 8.1 Discussion 162 8.1.1 The prevalence of constipation and laxative use 162 8.1.2 Factors associated with constipation in the community 165 8.1.3 Characterisation of laxative use in the community 167 8.2 Strengths and limitations 170 8.3 Conclusion 171 8.4 Recommendations for future research 172 8.5 References 173 Appendices Appendix 1: Survey questionnaire 177 Appendix 2: Ethics approval letter 192 Appendix 3: Participant information statement 195 vii viii Publications and Conference Presentations Arising from this Research Publications: Publication 1: Werth, B.L., Williams, K.A., & Pont, L.G. (2015). A longitudinal study of constipation and laxative use in a community-dwelling elderly population. Archives of Gerontology & Geriatrics 60,418- 424. Publication 2: Werth, B.L., Williams, K.A., & Pont, L.G. (2017). Laxative use and self-reported constipation in a community-dwelling elderly population. Gastroenterology Nursing 40 (2), 134-141. Publication 3: Werth, B.L. (2019). Epidemiology of constipation in adults: Why estimates of prevalence differ. Journal of Epidemiological Research 5(1),37-49. Publication 4: Werth, B.L., Williams, K.A., Fisher, M.J. & Pont, L.G. (2019). Defining constipation to estimate its prevalence in the community: results from a national survey. BMC Gastroenterology 19, 75. Conference Presentations: Oral presentations: Werth, B. (2013): Constipation and laxative use in a community-based elderly population, The 12th National Conference of Emerging Researchers in Ageing, Sydney, 25-26th Nov, 2013. Poster presentations: Werth, B. (2012): A longitudinal study of constipation and laxative use in a community-dwelling elderly population, ASCEPT-APSA Joint Conference, Sydney, 2-5th Dec, 2012. Werth, B. (2015): Laxative use and constipation in community-dwelling adults in Australia, ASCEPT- APSA Joint Scientific Meeting, Hobart, 29th Nov – 2nd Dec, 2015. ix x xi Acknowledgements This thesis would not have been possible without the assistance of many people and I wish to acknowledge the contributions of each. Firstly, my supervisory team must be acknowledged for their patience, support and generous amounts of time. I thank Professor Kylie Williams, my original primary supervisor, for taking me on in 2010 and finding the funds for the survey. Kylie’s academic experience and knowledge were invaluable in assisting me every step of the way. I appreciated being challenged with my writing and thinking, and will forever remember to ask the “so what?” question. I thank Associate Professor Murray Fisher, a latecomer to the team, for his expert guidance, professional judgement and encouragement to continue over the past few years. Murray was always available when needed and always provided sage advice. I am indebted to Associate Professor Lisa Pont, my primary supervisor for the bulk of my candidature. Lisa stuck with me even though she moved faculties and universities three times during my candidature. Lisa provided expert advice and tuition in the academic world. I have learned so much from Lisa whose intelligence and knowledge were inspirational. Throughout my lengthy candidature some adversities were encountered in the form of family tragedies, and personal illness and injury. The understanding and support provided by all supervisors at these difficult times was very much appreciated. Beyond the supervisory team, I also acknowledge the contributions of several others. At the School of Nursing and Midwifery, the support and encouragement provided by Associate Professor Tom Buckley, Associate Professor Jenny Fraser and especially Sybèle Christopher were instrumental in getting me through to the end. The expert statistical assistance provided by Judith Fethney, Sydney Nursing School Biostatistician, was invaluable in the analysis of data. I am very grateful for the generous amounts of time, helpful advice and patience provided by Judith. Also, I acknowledge the assistance provided by Associate Professors Terry Bolin (UNSW), Danny Stiel (USyd) and Philip Dinning (UNSW and now Flinders University) in reviewing the survey questionnaire. xii I must acknowledge and thank two special people who supported me along the way. At the beginning of my candidature, my late wife Trean encouraged me to pursue my ambition and assisted with some early work based on her nursing experience. Over the past few years, my partner Jennifer has helped me by understanding the time commitment required, encouraging me to continue whenever I contemplated giving it away and generally supporting me in my PhD endeavours. Finally, as a candidate of mature age, I thank the University of Sydney for approving my candidature and allowing me to pursue this research.
Load more

Recommended publications
  • Instruction Sheet: Constipation
    University of North Carolina Wilmington Abrons Student Health Center INSTRUCTION SHEET: CONSTIPATION The Student Health Provider has treated you for constipation. Constipation consists of a change from your usual pattern, with stools becoming less frequent and more difficult to pass. There is no set number of bowel movements a person should have each day or week. People vary widely in frequency of bowel movements, from three times a day to three times a week. Most everyone experiences constipation sometime in his/her life. Certain medicines, such as prescription pain pills, calcium antacids, calcium supplements, antihistamines, diet pills, calcium channel blockers, and diuretics (fluid pills) can cause constipation. Other factors which increase constipation include age, pregnancy, chronic laxative abuse, and a diet low in fiber. Americans, in general, consume a low fiber diet. Fiber acts as a natural laxative: Fiber draws water into the stool and increases the bulk of stools, resulting in softer stools and more rapid movement of stools through the intestine. Fiber in the diet not only minimizes constipation; fiber may prevent diverticulitis, hemorrhoids, intestinal polyps, and even cancer of the bowel. A high fiber diet is also helpful in weight control/reduction. MEASURES WHICH YOU SHOULD TAKE TO HELP TREAT AND PREVENT CONSTIPATION: 1. Drink plenty of fluids every day. Four to six glasses of water or other non-alcoholic beverage help keep stools soft. 2. Exercise daily. Even mild exercise like walking improves bowel function. 3. Consume a diet high in fiber. Fruits, vegetables, whole wheat bread, oatmeal, and bran cereal are all high in fiber.
    [Show full text]
  • Peptide Therapeutics Designing a Science-Led Strategic Quality Control Program
    BioProcess International Peptide SPECIAL REPORT Therapeutics Designing a Science-Led Strategic Quality Control Program INTERTEK PHARMACEUTICAL SERVICES Your partner for regulatory-driven, phase appropriate analytical programs tailored to your molecule. Our experts help you to navigate the challenges of development, regulatory submission, and manufacturing. Peptide Therapeutics Designing a Science-Led Strategic Quality Control Program Shashank Sharma and Hannah Lee ince the emergence of peptide therapeutics in the 1920s with the advent of insulin therapy, the market for this product class has continued to expand with global revenues anticipatedS to surpass US$50 billion by 2024 (1). The growth of peptide therapeutics is attributed not only to improvements in manufacturing, but also to a rise in demand because of an increasingly aging population that is driving an increase in the occurrence of long-term diseases. The need for efficient and low-cost drugs and rising investments in research and development of novel drugs continues to boost market growth and fuel the emergence of generic versions that offer patients access to vital medicines at low costs. North America has been the dominant market for peptide therapeutics, with the Asia–Pacific region Insulin molecular model; the first therapeutic expected to grow at a faster rate. The global peptides use of this peptide hormone was in the market has attracted the attention of key players 1920s to treat diabetic patients. within the pharmaceutical industry, including Teva Pharmaceuticals, Eli Lilly, Novo Nordisk, Pfizer, amino acids to be peptides. Within that set, those Takeda, and Amgen. Those companies have made containing 10 or more are classed as polypeptides.
    [Show full text]
  • Medicines That Affect Fluid Balance in the Body
    the bulk of stools by getting them to retain liquid, which encourages the Medicines that affect fluid bowels to push them out. balance in the body Osmotic laxatives e.g. Lactulose, Macrogol - these soften stools by increasing the amount of water released into the bowels, making them easier to pass. Older people are at higher risk of dehydration due to body changes in the ageing process. The risk of dehydration can be increased further when Stimulant laxatives e.g. Senna, Bisacodyl - these stimulate the bowels elderly patients are prescribed medicines for chronic conditions due to old speeding up bowel movements and so less water is absorbed from the age. stool as it passes through the bowels. Some medicines can affect fluid balance in the body and this may result in more water being lost through the kidneys as urine. Stool softener laxatives e.g. Docusate - These can cause more water to The medicines that can increase risk of dehydration are be reabsorbed from the bowel, making the stools softer. listed below. ANTACIDS Antacids are also known to cause dehydration because of the moisture DIURETICS they require when being absorbed by your body. Drinking plenty of water Diuretics are sometimes called 'water tablets' because they can cause you can reduce the dry mouth, stomach cramps and dry skin that is sometimes to pass more urine than usual. They work on the kidneys by increasing the associated with antacids. amount of salt and water that comes out through the urine. Diuretics are often prescribed for heart failure patients and sometimes for patients with The major side effect of antacids containing magnesium is diarrhoea and high blood pressure.
    [Show full text]
  • Linaclotide: a Novel Therapy for Chronic Constipation and Constipation- Predominant Irritable Bowel Syndrome Brian E
    Linaclotide: A Novel Therapy for Chronic Constipation and Constipation- Predominant Irritable Bowel Syndrome Brian E. Lacy, PhD, MD, John M. Levenick, MD, and Michael D. Crowell, PhD, FACG Dr. Lacy is Section Chief of Gastroenter- Abstract: Chronic constipation and irritable bowel syndrome ology and Hepatology and Dr. Levenick (IBS) are functional gastrointestinal disorders that significantly is a Gastroenterology Fellow in the affect patients’ quality of life. Chronic constipation and IBS are Division of Gastroenterology and prevalent—12% of the US population meet the diagnostic crite- Hepatology at Dartmouth-Hitchcock Medical Center in Lebanon, New ria for IBS, and 15% meet the criteria for chronic constipation— Hampshire. Dr. Crowell is a Professor and these conditions negatively impact the healthcare system of Medicine in the Division of from an economic perspective. Despite attempts at dietary Gastroenterology and Hepatology at modification, exercise, or use of over-the-counter medications, Mayo Clinic in Scottsdale, Arizona. many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Address correspondence to: Dr. Brian E. Lacy Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, first- Division of Gastroenterology and in-class medication for the treatment of chronic constipation Hepatology, Area 4C and constipation-predominant IBS. Dartmouth-Hitchcock Medical Center 1 Medical Center Drive Lebanon, NH 03756; Tel: 603-650-5215; Fax: 603-650-5225; onstipation is
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Chronic Constipation: an Evidence-Based Review
    J Am Board Fam Med: first published as 10.3122/jabfm.2011.04.100272 on 7 July 2011. Downloaded from CLINICAL REVIEW Chronic Constipation: An Evidence-Based Review Lawrence Leung, MBBChir, FRACGP, FRCGP, Taylor Riutta, MD, Jyoti Kotecha, MPA, MRSC, and Walter Rosser MD, MRCGP, FCFP Background: Chronic constipation is a common condition seen in family practice among the elderly and women. There is no consensus regarding its exact definition, and it may be interpreted differently by physicians and patients. Physicians prescribe various treatments, and patients often adopt different over-the-counter remedies. Chronic constipation is either caused by slow colonic transit or pelvic floor dysfunction, and treatment differs accordingly. Methods: To update our knowledge of chronic constipation and its etiology and best-evidence treat- ment, information was synthesized from articles published in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Levels of evidence and recommendations were made according to the Strength of Recommendation taxonomy. Results: The standard advice of increasing dietary fibers, fluids, and exercise for relieving chronic constipation will only benefit patients with true deficiency. Biofeedback works best for constipation caused by pelvic floor dysfunction. Pharmacological agents increase bulk or water content in the bowel lumen or aim to stimulate bowel movements. Novel classes of compounds have emerged for treating chronic constipation, with promising clinical trial data. Finally, the link between senna abuse and colon cancer remains unsupported. Conclusions: Chronic constipation should be managed according to its etiology and guided by the best evidence-based treatment.(J Am Board Fam Med 2011;24:436–451.) copyright. Keywords: Chronic Constipation, Clinical Review, Evidence-Based Medicine, Family Medicine, Gastrointestinal Problems, Systematic Review The word “constipation” has varied meanings for was established in 1991 by Drossman et al, primar- different individuals.
    [Show full text]
  • Bowel Management When Taking Pain Or Other Constipating Medicine
    Bowel Management When Taking Pain or Other Constipating Medicine How Medicines Affect Bowel Function Pain medication and some chemotherapy and anti-nausea medicines commonly cause severe constipation. They affect the digestive system by: Slowing down the movement of body waste (stool) in the large bowel (colon). Removing more water than normal from the colon. Preventing Constipation Before taking opioid pain medicine or beginning chemotherapy, it is a good idea to clean out your colon by taking laxatives of your choice. If you have not had a bowel movement for five or more days, ask your nurse for advice on how to pass a large amount of stool from your colon. After beginning treatment, you can prevent constipation by regularly taking stimulant laxatives and stool softeners. These will counteract the effects of the constipating medicines. For example, Senna (a stimulant laxative) helps move stool down in the colon and docusate sodium (a stool softener) helps soften it by keeping water in the stool. Brand names of combination stimulant laxatives and stool softeners are Senna-S® and Senokot-S®. The ‘S’ is the stool softener of these products. You can safely take up to eight Senokot-S or Senna-S pills in generic form per day. Start at the dose advised by your nurse. Gradually increase the dosage until you have soft-formed stools on a regular basis. Do not exceed 500 milligrams (mg) of docusate sodium per day if you are taking the stool softener separate from Senokot-S or Senna-S generic. Stool softeners, stimulant laxatives and combination products can be purchased without a prescription at drug and grocery stores.
    [Show full text]
  • Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-Analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation
    This is a repository copy of Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/149160/ Version: Accepted Version Article: Black, CJ, Burr, NE orcid.org/0000-0003-1988-2982 and Ford, AC orcid.org/0000-0001-6371-4359 (2020) Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation. Clinical Gastroenterology and Hepatology, 18 (5). 1238-1239.E1. ISSN 1542-3565 https://doi.org/10.1016/j.cgh.2019.07.007 © 2019 by the AGA Institute. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/). Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Black et al. Page 1 of 9 Accepted for publication 3rd July 2019 TITLE PAGE Title: Relative Efficacy of Tegaserod in a Systematic Review and Network Meta- analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation.
    [Show full text]
  • Having a Barium Enema.Pdf
    Information for patients having a barium enema About this leaflet However, during the barium enema, you will The leaflet tells you about having a barium be exposed to the same amount of radiation enema. It explains what is involved and what as you would receive naturally from the the possible risks are. It is not meant to atmosphere over about three years. replace informed discussion between you There is also a tiny risk of making a small and your doctor, but can act as a starting hole in the bowel, a perforation. This point for such discussions. If you have any happens very rarely and generally only if questions about the procedure please ask there is a problem like a severe inflammation the doctor who has referred you for the test of the bowel wall. or the department which is going to perform it. There is also some slight risk if you are given an injection of Hyoscine Butylbromide The radiology department (a muscle relaxant) to relax the bowel. The The department may also be called the X- radiologist or radiographer will ask you if you ray or imaging department. It is the facility in have any history of glaucoma before giving the hospital where radiological examinations this injection as this may affect the muscles of patients are carried out, using a range of of the eye. equipment, such as a CT (computed The risks from missing a serious disorder by tomography) scanner, an ultrasound not having this investigation are machine and an MRI (magnetic resonance considerably greater. imaging) scanner.
    [Show full text]
  • Do Routine Eye Exams Reduce Occurrence of Blindness from Type 2
    JFP_09.04_CI_finalREV 8/25/04 2:22 PM Page 732 Clinical Inquiries F ROM T HE F AMILY P RACTICE I NQUIRIES N ETWORK Do routine eye exams reduce photography. Median follow-up was 3.5 years occurrence of blindness (range, 1–8.5 years). from type 2 diabetes? The patients were divided into cohorts based on level of demonstrated retinopathy. The mean screening interval for a 95% probability of remaining free of sight-threatening retinopathy ■ EVIDENCE-BASED ANSWER was calculated for each grade of baseline Screening eye exams for patients with type 2 retinopathy. Screening patients with no retino- diabetes can detect retinopathy early enough so pathy every 5 years provided a 95% probability of treatment can prevent vision loss. Patients with- remaining free of sight-threatening retinopathy. out diabetic retinopathy who are systematically Patients with background retinopathy must be screened by mydriatic retinal photography have a screened annually to achieve the same result, and 95% probability of remaining free of sight-threat- patients with mild preproliferative retinopathy ening retinopathy over the next 5 years. If back- need to be screened every 4 months (Table). ground or preproliferative retinopathy is found at A systematic review2 of multiple small English- screening (Figure), the 95% probability interval language studies evaluating screening and moni- for remaining free of sight-threatening retino- toring of diabetic retinopathy found consistent pathy is reduced to 12 and 4 months, respective- results. Screening by direct or indirect ophthal- ly (strength of recommendation [SOR]: B, based moscopy alone detected 65% of patients with on 1 prospective cohort study).
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 26, No. 4, 2012 WHO Drug Information Contents International Regulatory Regulatory Action and News Harmonization New task force for antibacterial International Conference of Drug drug development 383 Regulatory Authorities 339 NIBSC: new MHRA centre 383 Quality of medicines in a globalized New Pakistan drug regulatory world: focus on active pharma- authority 384 ceutical ingredients. Pre-ICDRA EU clinical trial regulation: public meeting 352 consultation 384 Pegloticase approved for chronic tophaceous gout 385 WHO Programme on Tofacitinib: approved for rheumatoid International Drug Monitoring arthritis 385 Global challenges in medicines Rivaroxaban: extended indication safety 362 approved for blood clotting 385 Omacetaxine mepesuccinate: Safety and Efficacy Issues approved for chronic myelo- Dalfampridine: risk of seizure 371 genous leukaemia 386 Sildenafil: not for pulmonary hyper- Perampanel: approved for partial tension in children 371 onset seizures 386 Interaction: proton pump inhibitors Regorafenib: approved for colorectal and methotrexate 371 cancer 386 Fingolimod: cardiovascular Teriflunomide: approved for multiple monitoring 372 sclerosis 387 Pramipexole: risk of heart failure 372 Ocriplasmin: approved for vitreo- Lyme disease test kits: limitations 373 macular adhesion 387 Anti-androgens: hepatotoxicity 374 Florbetapir 18F: approved for Agomelatine: hepatotoxicity and neuritic plaque density imaging 387 liver failure 375 Insulin degludec: approved for Hypotonic saline in children: fatal diabetes mellitus
    [Show full text]